Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma

CD133 and nuclear β-catenin: The marker combination to detect high risk cases of low stage colorectal cancer

(2009) David Horst et al.   EUROPEAN JOURNAL OF CANCER

Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer

(2009) Qi Wang et al.   HISTOPATHOLOGY

Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma

(2009) Dongho Choi et al.   WORLD JOURNAL OF GASTROENTEROLOGY

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

(2008) L M Smith et al.   BRITISH JOURNAL OF CANCER

CD133 expression is an independent prognostic marker for low survival in colorectal cancer

(2008) D Horst et al.   BRITISH JOURNAL OF CANCER

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunohistochemical detection of CD133 expression in colorectal cancer: A clinicopathological study

(2008) Motohiro Kojima et al.   CANCER SCIENCE

Fhit tumor suppressor: guardian of the preneoplastic genome

(2008) Flavia Pichiorri et al.   Future Oncology

Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity

(2008) L. Vermeulen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA